Skip to content
Menu

Valion Bio Confirms Receipt Of Proposed Acquisition Offers For Its Velocity Bioworks; Terms Undisclosed

Benzinga Newsdesk 3 weeks ago

M&A

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation,

Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today announced that it has received unsolicited acquisition inquiries from independent third parties concerning its wholly owned contract development and manufacturing organization ("CDMO"), Velocity Bioworks ("Velocity"). The Company has entered into preliminary discussions with these interested parties while continuing to evaluate a range of strategic options for Velocity.

Read at benzinga.com